Articles

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioresorbable vascular scaffold (BVS) is more cost effective and offers a...

ABSORB II Study DES Xience Abbot Vascular

Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb...

bioresorbable stents, dissolving stents, Absorb stent, BVS

A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC) meetings is that bioresorbable stents...

Elixir Medical Corp. DESolve 100 CE mark

Elixir Medical Corp. received CE mark approval for its DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System.

April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the company's Absorb bioresorbable vascular scaffold (BVS) in the United States,...

Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent

Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo Corp. Under the agreement, ART and Terumo Corp. will collaborate in the development of a drug...

cath lab stents bioresorbable amaranth fortitude scaffold

Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp.

ACC, iPad cardiology apps

DAIC readers chose the following stories as the most popular content in 2013, based on website analytics.

stents bioresorbable cath lab intravascular imaging clinical trial study abbott

The Cardiovascular Research Foundation (CRF) and the Uppsala Clinical Research Center (UCR) of Uppsala, Sweden announced the initiation of the Providing Regional Observations to Study Predictors...